PSMA Tracer Linker Charge Modification for Tumor Contrast
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current PSMA-targeting radiolabeled tracers for prostate cancer imaging suffer from non-specific background binding, leading to reduced sensitivity and increased toxicity due to hydrophobic interactions and elevated liver and blood pool retention.
Innovation Solution
Design of PSMA tracers with highly negatively charged linkers that connect to urea inhibitors and bulky radionuclide chelates, which exhibit rapid renal excretion and minimal non-specific binding, improving tumor-to-background contrast in positron emission tomography.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If hydrophobic linkers are used to connect radionuclide chelates to PSMA inhibitors, then the tracer can be synthesized, but non-specific background binding increases and tumor-to-background contrast decreases
Solution Approach 1:
The patent changes the chemical parameter of the linker from hydrophobic to highly negatively charged (hydrophilic). This parameter change fundamentally alters the tracer's interaction with biological tissues, eliminating non-specific hydrophobic binding to proteins and membranes while maintaining specific binding to PSMA through the urea inhibitor portion of the molecule.
Solution Approach 2:
The patent applies local quality by creating a linker with distinct chemical properties (highly negatively charged) that is localized to the connection region between the radionuclide chelate and the PSMA inhibitor. This localized chemical modification allows the tracer to have different interaction properties at different regions: the charged linker avoids non-specific binding while the urea inhibitor maintains specific target binding.
2Ease of operation
If conventional PSMA tracers are used, then imaging can be performed, but liver and blood pool retention increases causing elevated background and potential toxicity
Solution Approach 1:
The patent changes the charge parameter of the linker to highly negative, which fundamentally alters the tracer's biodistribution. This parameter change prevents the tracer from accumulating in the liver and blood pool by eliminating hydrophobic interactions, while still allowing renal excretion and specific PSMA binding to occur.
3Measurement precision
If PSMA-targeting tracers with improved specificity are designed, then tumor detection sensitivity increases, but the molecular structure becomes more complex
Solution Approach 1:
The patent applies local quality by modifying only the linker region of the molecule while keeping the PSMA-binding urea inhibitor portion simple and unchanged. This localized modification achieves improved tumor detection sensitivity through reduced background binding without requiring complex changes to the entire molecular structure.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The use of highly negatively charged linkers in PSMA tracers reduces non-specific background binding, enhancing tumor detection sensitivity while minimizing radiation exposure and toxicity, with improved tumor-to-background ratios.
Implementation Method 1
The use of highly negatively charged linkers in PSMA tracers reduces non-specific background binding
Implementation Method 2
PSMA-targeting imaging agents
Data Source
AI summary
A PSMA-specific imaging agent comprising a compound according to formula I:are described, wherein S1 is an organic spacer group having from 5 to 30 carbons, A is an amino acid forming a portion of a negatively charged peptide oligomer, n is from 3 to 6, S2 is an organic spacer group having from 5 to 15 carbons, and I is an imaging group, and pharmaceutically acceptable salts thereof. The PSMA-specific imaging agents can be used to image PSMA within a tissue region to guide the treatment of diseases such as prostate cancer.